China’s PD-(L)1 × VEGF Bispecific Boom:
How Innovation and Investment Are Reshaping Global Oncology
The next era of immuno-oncology is being defined now. With China’s biotechs leading development and global pharma forging billion-dollar partnerships, PD-(L)1 × VEGF bispecific antibodies are emerging as a major therapeutic frontier.
Our latest analysis examines the rapidly evolving PD-(L)1 × VEGF bispecific antibody landscape, with a particular focus on the innovation momentum coming from China. This category is quickly becoming one of the most important areas in immuno-oncology, especially as the 2028 PD-(L)1 patent cliff approaches.
Key Highlights from the Analysis:
- China now leads with 17+ clinical assets, anchored by ivonescimab
- Global pharma companies have committed >$40 billion in combined deal value through major partnerships with Chinese innovators
- The regulatory demand for superiority to SOC continues to challenge entrants, but combination strategies with ADCs are opening new pathways
- Multiple global studies are planned for 2026, with pivotal readouts expected through 2027
- New tetravalent BsAbs and expansion into RCC, HCC, UC and additional indications will intensify competition
Don’t miss out – download your copy of this whitepaper by completing the form.